JPH11504018A - 硫酸化オリゴ糖の製造および使用 - Google Patents
硫酸化オリゴ糖の製造および使用Info
- Publication number
- JPH11504018A JPH11504018A JP8532038A JP53203896A JPH11504018A JP H11504018 A JPH11504018 A JP H11504018A JP 8532038 A JP8532038 A JP 8532038A JP 53203896 A JP53203896 A JP 53203896A JP H11504018 A JPH11504018 A JP H11504018A
- Authority
- JP
- Japan
- Prior art keywords
- sulfated
- oligosaccharide
- oligosaccharides
- inflammatory
- oligosaccharide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 182
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 162
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 230000002001 anti-metastasis Effects 0.000 claims abstract description 26
- 230000001772 anti-angiogenic effect Effects 0.000 claims abstract description 19
- 239000004037 angiogenesis inhibitor Substances 0.000 claims abstract description 8
- 239000002257 antimetastatic agent Substances 0.000 claims abstract description 8
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 7
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 46
- -1 chondroitin tetrasaccharide Chemical class 0.000 claims description 41
- 108010037536 heparanase Proteins 0.000 claims description 38
- 102100024025 Heparanase Human genes 0.000 claims description 36
- 230000033115 angiogenesis Effects 0.000 claims description 32
- 241001465754 Metazoa Species 0.000 claims description 27
- OCIBBXPLUVYKCH-QXVNYKTNSA-N alpha-maltohexaose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](O[C@H](O[C@@H]3[C@H](O[C@H](O[C@@H]4[C@H](O[C@H](O[C@@H]5[C@H](O[C@H](O)[C@H](O)[C@H]5O)CO)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O OCIBBXPLUVYKCH-QXVNYKTNSA-N 0.000 claims description 26
- 150000002772 monosaccharides Chemical group 0.000 claims description 26
- 241000282414 Homo sapiens Species 0.000 claims description 25
- DJMVHSOAUQHPSN-UHFFFAOYSA-N malto-hexaose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(OC4C(C(O)C(O)C(CO)O4)O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 DJMVHSOAUQHPSN-UHFFFAOYSA-N 0.000 claims description 25
- 230000002401 inhibitory effect Effects 0.000 claims description 23
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- 235000000346 sugar Nutrition 0.000 claims description 22
- 239000008103 glucose Substances 0.000 claims description 21
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 19
- FTNIPWXXIGNQQF-UHFFFAOYSA-N UNPD130147 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(OC4C(OC(O)C(O)C4O)CO)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O FTNIPWXXIGNQQF-UHFFFAOYSA-N 0.000 claims description 16
- YETHWGOYCQLNKG-FHERGOJNSA-N alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-D-Manp Chemical group O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@H]1O[C@@H]1[C@@H](O[C@@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YETHWGOYCQLNKG-FHERGOJNSA-N 0.000 claims description 15
- 229930182830 galactose Natural products 0.000 claims description 14
- 229910019142 PO4 Inorganic materials 0.000 claims description 13
- 239000010452 phosphate Substances 0.000 claims description 13
- 150000002402 hexoses Chemical group 0.000 claims description 11
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 10
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 10
- 150000004676 glycans Chemical class 0.000 claims description 10
- 229920001282 polysaccharide Polymers 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 9
- 210000000265 leukocyte Anatomy 0.000 claims description 9
- 239000005017 polysaccharide Substances 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- LUEWUZLMQUOBSB-UHFFFAOYSA-N UNPD55895 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(O)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O LUEWUZLMQUOBSB-UHFFFAOYSA-N 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- UYQJCPNSAVWAFU-UHFFFAOYSA-N malto-tetraose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)O1 UYQJCPNSAVWAFU-UHFFFAOYSA-N 0.000 claims description 7
- LUEWUZLMQUOBSB-OUBHKODOSA-N maltotetraose Chemical group O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O[C@@H]3[C@@H](O[C@@H](O)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-OUBHKODOSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 claims description 6
- 150000002453 idose derivatives Chemical class 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 5
- 230000008595 infiltration Effects 0.000 claims description 5
- 238000001764 infiltration Methods 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 4
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 4
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 4
- 208000023819 chronic asthma Diseases 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 4
- 229920002567 Chondroitin Polymers 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 241001489176 Nakazawaea holstii Species 0.000 claims description 3
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- FJCUPROCOFFUSR-UHFFFAOYSA-N malto-pentaose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 FJCUPROCOFFUSR-UHFFFAOYSA-N 0.000 claims description 3
- FJCUPROCOFFUSR-GMMZZHHDSA-N maltopentaose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)O)[C@@H](CO)O1 FJCUPROCOFFUSR-GMMZZHHDSA-N 0.000 claims description 3
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 3
- 230000004614 tumor growth Effects 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 2
- 239000005715 Fructose Substances 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 238000002144 chemical decomposition reaction Methods 0.000 claims description 2
- 208000037976 chronic inflammation Diseases 0.000 claims description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims description 2
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000001483 monosaccharide substituent group Chemical group 0.000 abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 42
- 229920002971 Heparan sulfate Polymers 0.000 description 36
- 230000000694 effects Effects 0.000 description 36
- 150000001875 compounds Chemical class 0.000 description 30
- 239000000047 product Substances 0.000 description 30
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 21
- 229960002897 heparin Drugs 0.000 description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 238000003556 assay Methods 0.000 description 18
- 229920000669 heparin Polymers 0.000 description 18
- 230000005764 inhibitory process Effects 0.000 description 17
- 239000003112 inhibitor Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 15
- 230000019635 sulfation Effects 0.000 description 15
- 238000005670 sulfation reaction Methods 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 206010027476 Metastases Diseases 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 239000000499 gel Substances 0.000 description 13
- 230000009401 metastasis Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000003102 growth factor Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 238000004587 chromatography analysis Methods 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 10
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 229920000642 polymer Polymers 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 101150021185 FGF gene Proteins 0.000 description 8
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 7
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 7
- 210000002469 basement membrane Anatomy 0.000 description 7
- 238000002523 gelfiltration Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000014508 negative regulation of coagulation Effects 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 241000235648 Pichia Species 0.000 description 6
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 201000002491 encephalomyelitis Diseases 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 229910021653 sulphate ion Inorganic materials 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102100027619 Histidine-rich glycoprotein Human genes 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 210000004712 air sac Anatomy 0.000 description 5
- 230000006427 angiogenic response Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 210000003979 eosinophil Anatomy 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 108010044853 histidine-rich proteins Proteins 0.000 description 5
- 229920001519 homopolymer Polymers 0.000 description 5
- 238000004452 microanalysis Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000011592 zinc chloride Substances 0.000 description 5
- 235000005074 zinc chloride Nutrition 0.000 description 5
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229920002444 Exopolysaccharide Polymers 0.000 description 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 4
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000002491 angiogenic effect Effects 0.000 description 4
- 229910052788 barium Inorganic materials 0.000 description 4
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical group [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 201000008275 breast carcinoma Diseases 0.000 description 4
- 239000003729 cation exchange resin Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229960002086 dextran Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 150000002692 maltoses Chemical class 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 229940071127 thioglycolate Drugs 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 206010038063 Rectal haemorrhage Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 108090000190 Thrombin Proteins 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- BNABBHGYYMZMOA-AHIHXIOASA-N alpha-maltoheptaose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)O[C@H](O[C@@H]2[C@H](O[C@H](O[C@@H]3[C@H](O[C@H](O[C@@H]4[C@H](O[C@H](O[C@@H]5[C@H](O[C@H](O[C@@H]6[C@H](O[C@H](O)[C@H](O)[C@H]6O)CO)[C@H](O)[C@H]5O)CO)[C@H](O)[C@H]4O)CO)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O BNABBHGYYMZMOA-AHIHXIOASA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- ITHZDDVSAWDQPZ-UHFFFAOYSA-L barium acetate Chemical compound [Ba+2].CC([O-])=O.CC([O-])=O ITHZDDVSAWDQPZ-UHFFFAOYSA-L 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 229960000633 dextran sulfate Drugs 0.000 description 3
- 150000002016 disaccharides Chemical group 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 3
- UDYFLDICVHJSOY-UHFFFAOYSA-N sulfur trioxide-pyridine complex Substances O=S(=O)=O.C1=CC=NC=C1 UDYFLDICVHJSOY-UHFFFAOYSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002381 testicular Effects 0.000 description 3
- 229960004072 thrombin Drugs 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- PZUPAGRIHCRVKN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]-5-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound OCC1OC(O)C(O)C(O)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(COC4C(C(O)C(O)CO4)O)O3)O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(COC2C(C(O)C(O)CO2)O)O1 PZUPAGRIHCRVKN-UHFFFAOYSA-N 0.000 description 2
- 229920000856 Amylose Polymers 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 229940122588 Heparanase inhibitor Drugs 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- LHAOFBCHXGZGOR-NAVBLJQLSA-N alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1 LHAOFBCHXGZGOR-NAVBLJQLSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229910001422 barium ion Inorganic materials 0.000 description 2
- FYGDTMLNYKFZSV-XJJKTWKOSA-N beta-(1->4)-galactotriose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H](CO)O[C@@H](O[C@H]2[C@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-XJJKTWKOSA-N 0.000 description 2
- OCIBBXPLUVYKCH-KKQGKRJZSA-N beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-D-Manp Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3[C@H](O[C@@H](O[C@@H]4[C@H](O[C@@H](O[C@@H]5[C@H](OC(O)[C@@H](O)[C@H]5O)CO)[C@@H](O)[C@H]4O)CO)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@@H](O)[C@H]1O OCIBBXPLUVYKCH-KKQGKRJZSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 238000006345 epimerization reaction Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- DBTMGCOVALSLOR-AXAHEAMVSA-N galactotriose Natural products OC[C@@H]1O[C@@H](O[C@@H]2[C@@H](O)[C@H](CO)O[C@@H](O[C@H]3[C@@H](O)[C@H](O)O[C@@H](CO)[C@@H]3O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O DBTMGCOVALSLOR-AXAHEAMVSA-N 0.000 description 2
- 125000002367 glucuronosyl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 229910017053 inorganic salt Inorganic materials 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 2
- 229960005314 suramin Drugs 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 150000004044 tetrasaccharides Chemical class 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 239000011547 Bouin solution Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 238000006945 Knorr synthesis reaction Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 101100123313 Mus musculus H1.8 gene Proteins 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- AYRXSINWFIIFAE-UHFFFAOYSA-N O6-alpha-D-Galactopyranosyl-D-galactose Natural products OCC1OC(OCC(O)C(O)C(O)C(O)C=O)C(O)C(O)C1O AYRXSINWFIIFAE-UHFFFAOYSA-N 0.000 description 1
- LWEKTYPJQXLBJQ-VFUOTHLCSA-N O[C@H]1[C@H]2[C@@H](O)[C@H](O)[C@H](O1)CO2 Chemical compound O[C@H]1[C@H]2[C@@H](O)[C@H](O)[C@H](O1)CO2 LWEKTYPJQXLBJQ-VFUOTHLCSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- GTNWKUALJZLKRF-RMPHRYRLSA-N [(2r,3r,4s,5r,6r)-4,5-diacetyloxy-6-bromo-6-hydroxy-2-(hydroxymethyl)oxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1[C@@H](CO)O[C@@](O)(Br)[C@H](OC(C)=O)[C@H]1OC(C)=O GTNWKUALJZLKRF-RMPHRYRLSA-N 0.000 description 1
- FEQXFAYSNRWXDW-RKQHYHRCSA-N [(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(hydroxymethyl)oxan-3-yl] acetate Chemical compound CC(=O)O[C@@H]1O[C@H](CO)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O FEQXFAYSNRWXDW-RKQHYHRCSA-N 0.000 description 1
- YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000013567 aeroallergen Substances 0.000 description 1
- 230000009603 aerobic growth Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- FBJQEBRMDXPWNX-CFCQXFMMSA-N beta-D-Glcp-(1->6)-beta-D-Glcp-(1->6)-beta-D-Glcp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC[C@@H]2[C@H]([C@H](O)[C@@H](O)[C@H](O)O2)O)O1 FBJQEBRMDXPWNX-CFCQXFMMSA-N 0.000 description 1
- LUEWUZLMQUOBSB-MHJOMNRISA-N beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-beta-D-Manp-(1->4)-D-Manp Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3[C@H](OC(O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@@H](O)[C@H]1O LUEWUZLMQUOBSB-MHJOMNRISA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002243 furanoses Chemical class 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- DLRVVLDZNNYCBX-CQUJWQHSSA-N gentiobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-CQUJWQHSSA-N 0.000 description 1
- 125000002566 glucosaminyl group Chemical group 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 125000003103 iduronosyl group Chemical group 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229930190071 lycoside Natural products 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000012313 reversal agent Substances 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 210000001991 scapula Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.オリゴ糖が一般式I: R1−(Rx)n−R2 (I) [式中、R1およびR2ならびに各Rxは、単糖単位を表し、その全ては、同一ま たは異なっており、隣接する単糖単位は、1→2、1→3、1→4および/また は1→6グリコシド結合によって結合されており、 nは、1〜6の整数である] で示される硫酸化オリゴ糖。 2.nが1〜4、好ましくは、3または4である請求項1記載の硫酸化オリゴ 糖。 3.単糖単位が、フルクトース、グルコース、マンノース、アルトロース、ア ロース、タロース、ガラクトース、イドースおよびグロースからなる群から選択 されるヘキソースである請求項1または2記載の硫酸化オリゴ糖。 4.オリゴ糖が一般式II: Ry−(Ry)n−Ry (II) [式中、各Ryは、同一であり、各々、単糖単位を表しており、隣接する単糖単 位は、1→3、1→4および/または1→6グリコシド結合によって結合されて おり、 nは、1〜6の整数である] で示される請求項1記載の硫酸化オリゴ糖。 5.nが1〜4、好ましくは、3または4である請求項4記載の硫酸化オリゴ 糖。 6.Ryが、グルコース、マンノース、アルトロース、アロース、タロース、 ガラクトース、イドースおよびグロースからなる群から選択されるヘキソースで ある単糖単位を表す請求項4または5記載の硫酸化オリゴ糖。 7.Ryがグルコース、マンノースまたはガラクトースを表す請求項6記載の 硫酸化オリゴ糖。 8.オリゴ糖が天然オリゴ糖である請求項1記載の硫酸化オリゴ糖。 9.オリゴ糖がラフィノースおよびスタキオースから選択される請求項8記載 の硫酸化オリゴ糖。 10.オリゴ糖が天然多糖の酵素的または化学的分解によって製造される請求 項1記載の硫酸化オリゴ糖。 11.オリゴ糖が、アミロース−、コンドロイチン−またはデキストラン−誘 導オリゴ糖である請求項10記載の硫酸化オリゴ糖。 12.オリゴ糖が、マルトテトラオース、マルトペンタオース、マルトヘキサ オース、グルコトリオース、グルコテトラオース、グルコペンタオース、ならび にコンドロイチン四糖、六糖および八糖から選択される請求項11記載の硫酸化 オリゴ糖。 13.オリゴ糖が酵母ピキア・ホルスティ(Pichia holstii)由来のマンノ ペンタオースリン酸である請求項10記載の硫酸化オリゴ糖。 14.請求項1〜13のいずれか1項記載の少なくとも1つの硫酸化オリゴ糖 の有効量を患者に投与することを特徴とする、治療を必要とするヒトまたは他の 温血動物患者の抗脈管形成、抗転移および/または抗炎症治療方法。 15.温血動物(ヒトを含む)患者の治療における抗脈管形成剤、抗転移剤お よび/または抗炎症剤としての請求項1〜13のいずれか1項記載の硫酸化オリ ゴ糖の使用。 16.治療が、充実性腫瘍の増殖、増殖性網膜症および慢性関節リウマチに関 連する脈管形成を含む脈管形成依存性疾患の治療からなる請求項14または15 記載の方法または使用。 17.治療が、慢性関節リウマチなどの慢性炎症性疾患、多発性硬化症、イン スリン依存性真性糖尿病、潰瘍性大腸炎およびクローン炎症性大腸疾患などの疾 患、同種異系移植片拒絶反応ならびに慢性喘息を含む、ヘパラナーゼ阻害活性が 白血球浸潤を阻害する炎症性疾患および症状の治療からなる請求項14または1 5記載の方法または使用。 18.請求項1〜13のいずれか1項記載の少なくとも1つの硫酸化オリゴ糖 を医薬的および獣医学的に許容される担体または希釈剤と一緒に含有してなる、 抗脈管形成、抗転移および/または抗炎症治療のための医薬組成物または獣医学 的組成物。 19.ヒトまたは他の温血動物患者の抗脈管形成、抗転移および/または抗炎 症治療薬の製造における請求項1〜13のいずれか1項記載の少なくとも1つの 硫酸化オリゴ糖の使用。 20.一般式II: Ry−(Ry)n−Ry (II) [式中、各Ryは、同一であり、各々、単糖単位を表しており、隣接する単糖単 位は、1→3、1→4および/または1→6グリコシド結合によって結合されて おり、 nは、1〜6の整数である] で示されるオリゴ糖。 21.nが1〜4、好ましくは、3または4である請求項20記載のオリゴ糖 。 22.Ryが、グルコース、マンノース、アルトロース、アロース、タロース 、ガラクトース、イドースおよびグロースからなる群から選択されるヘキソース である単糖単位を表す請求項20または21記載のオリゴ糖。 23.Ryがグルコース、マンノースまたはガラクトースを表す請求項22記 載のオリゴ糖。 24.Ryが完全にO−アセチル化された単糖であるか、または、Ryがアセチ ル以外のアシル基で完全にO−アセチル化された単糖である請求項20記載のオ リゴ糖。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2618 | 1995-04-28 | ||
AUPN2618A AUPN261895A0 (en) | 1995-04-28 | 1995-04-28 | Preparation and use of sulfated oligosaccharides |
PCT/AU1996/000238 WO1996033726A1 (en) | 1995-04-28 | 1996-04-24 | Preparation and use of sulfated oligosaccharides |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009138310A Division JP2009235085A (ja) | 1995-04-28 | 2009-06-09 | 硫酸化オリゴ糖の製造および使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11504018A true JPH11504018A (ja) | 1999-04-06 |
JP4514240B2 JP4514240B2 (ja) | 2010-07-28 |
Family
ID=3786969
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53203896A Expired - Lifetime JP4514240B2 (ja) | 1995-04-28 | 1996-04-24 | 硫酸化オリゴ糖の製造および使用 |
JP2009138310A Withdrawn JP2009235085A (ja) | 1995-04-28 | 2009-06-09 | 硫酸化オリゴ糖の製造および使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009138310A Withdrawn JP2009235085A (ja) | 1995-04-28 | 2009-06-09 | 硫酸化オリゴ糖の製造および使用 |
Country Status (26)
Country | Link |
---|---|
US (1) | US6143730A (ja) |
EP (1) | EP0837683B1 (ja) |
JP (2) | JP4514240B2 (ja) |
KR (1) | KR100591960B1 (ja) |
CN (1) | CN1090021C (ja) |
AT (1) | ATE463250T1 (ja) |
AU (1) | AUPN261895A0 (ja) |
BR (1) | BR9608041B8 (ja) |
CA (1) | CA2218872C (ja) |
CZ (1) | CZ341097A3 (ja) |
DE (1) | DE69638158D1 (ja) |
EA (1) | EA001199B1 (ja) |
EE (1) | EE9700277A (ja) |
ES (1) | ES2341924T3 (ja) |
FI (1) | FI974060A0 (ja) |
HU (1) | HUP9802394A2 (ja) |
IL (1) | IL118047A (ja) |
IS (1) | IS4596A (ja) |
NO (1) | NO974911L (ja) |
NZ (1) | NZ305815A (ja) |
PL (1) | PL184357B1 (ja) |
PT (1) | PT837683E (ja) |
TR (1) | TR199701264T1 (ja) |
TW (1) | TW446710B (ja) |
WO (1) | WO1996033726A1 (ja) |
ZA (1) | ZA963339B (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001513569A (ja) * | 1997-08-28 | 2001-09-04 | ユニバーシティ・オブ・ワシントン | アルツハイマー病および他のアミロイド症を治療するための特定の糖組成物 |
JP2002029974A (ja) * | 2000-07-10 | 2002-01-29 | Seikagaku Kogyo Co Ltd | 脱髄性疾患処置剤 |
JP2010506858A (ja) * | 2006-10-20 | 2010-03-04 | ジ オーストラリアン ナショナル ユニバーシティ | 細胞外マトリクスの分解の阻害 |
WO2011122321A1 (ja) * | 2010-03-29 | 2011-10-06 | 国立大学法人名古屋大学 | ヘパリン結合性蛋白に対する生理活性阻害剤 |
JP2014516058A (ja) * | 2011-06-09 | 2014-07-07 | 基亜生物科技股▲ふん▼有限公司 | 肝癌の再発、悪化または転移の抑制に用いる医薬組成物 |
JP2015164947A (ja) * | 2007-10-16 | 2015-09-17 | プロジェン ファーマシューティカルズ リミテッド | 新規硫酸化オリゴ糖誘導体 |
JP2016199579A (ja) * | 2016-07-08 | 2016-12-01 | 基亜生物科技股▲ふん▼有限公司Medigen Biotechnology Corp. | 肝癌の再発、悪化または転移の抑制に用いる医薬組成物 |
JP2018109039A (ja) * | 2018-02-22 | 2018-07-12 | 基亜生物科技股▲ふん▼有限公司Medigen Biotechnology Corp. | 肝癌の再発、悪化または転移の抑制に用いる医薬組成物 |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPO556297A0 (en) * | 1997-03-11 | 1997-04-10 | Australian National University, The | Sulfated oligosaccharides having anticoagulant/ antithrombotic activity |
AUPO888497A0 (en) * | 1997-09-01 | 1997-09-25 | Australian National University, The | Use of sulfated oligosaccharides as inhibitors of cardiovascular disease |
AUPO976897A0 (en) * | 1997-10-14 | 1997-11-06 | Australian National University, The | Use of sulfated oligosaccharides in lowering blood triglyceride levels |
GB9802725D0 (en) | 1998-02-09 | 1998-04-08 | Ciba Geigy Ag | Organic compounds |
US7081448B2 (en) * | 1998-11-24 | 2006-07-25 | Wyeth | Benzyllactobionamides as inhibitors of smooth muscle cell proliferation |
US7132402B2 (en) * | 1998-11-24 | 2006-11-07 | Wyeth | Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation |
US20040220103A1 (en) * | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
US6083933A (en) * | 1999-04-19 | 2000-07-04 | Stellar International Inc. | Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution |
GB0001481D0 (en) * | 2000-01-21 | 2000-03-15 | Theryte Ltd | System for delivering a medicament |
GB0003048D0 (en) * | 2000-02-11 | 2000-03-29 | Dealler Stephen F | The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism |
FR2808687B1 (fr) * | 2000-04-27 | 2003-12-05 | Goemar Lab Sa | Medicament contenant des substances polysaccharidiques pour l'activation de l'apoptose |
US7407773B2 (en) * | 2000-11-03 | 2008-08-05 | Procognia, Ltd. | Method for characterizing a carbohydrate polymer |
TW519716B (en) * | 2000-12-19 | 2003-02-01 | Tokyo Electron Ltd | Wafer bias drive for a plasma source |
AU2002243630A1 (en) * | 2001-01-23 | 2002-08-06 | Massachusetts Institute Of Technology | Solid- and solution -phase synthesis of heparin and other glycosaminoglycans |
CN1394867A (zh) * | 2001-07-06 | 2003-02-05 | 中国科学院生态环境研究中心 | 可作药物的寡糖和其制备方法及含该寡糖的药物组合物 |
CZ307433B6 (cs) | 2001-09-12 | 2018-08-22 | Leadiant Biosciences Sa | Deriváty částečně desulfátovaných glykosaminoglykanů jako inhibitory heparanázy mající antiangiogenní účinky a zabraňující antikoagulačnímu působení |
KR20030046810A (ko) * | 2001-12-06 | 2003-06-18 | 은삼제약 주식회사 | 콘드로이친 황산의 분해산물을 포함하는 관절염 예방 또는치료용 약학적 조성물 |
AUPS052802A0 (en) * | 2002-02-15 | 2002-03-07 | Praxis Pharmaceuticals International Pty Ltd | Carbohydrate-based anti-wrinkle and tissue remodelling compounds |
US7575886B2 (en) * | 2002-03-11 | 2009-08-18 | Momenta Pharmaceuticals, Inc. | Analysis of sulfated polysaccharides |
US20040161476A1 (en) * | 2003-02-19 | 2004-08-19 | Hahn Sungtack Samuel | Cystitis treatment with high dose chondroitin sulfate |
WO2005054493A2 (en) * | 2003-06-12 | 2005-06-16 | Mayo Foundation For Medical Education And Research | Altered activity of toll-like receptors |
AU2005219456B2 (en) * | 2004-03-04 | 2011-04-07 | Progen Pharmaceuticals Limited | Sulfated oligosaccharide derivatives |
US9139876B1 (en) | 2007-05-03 | 2015-09-22 | Momenta Pharmacueticals, Inc. | Method of analyzing a preparation of a low molecular weight heparin |
AU2008255565B2 (en) * | 2007-05-31 | 2013-10-24 | Paradigm Biopharmaceuticals Ltd | Sulphated xylans for treatment or prophylaxis of respiratory diseases |
FR2917971B1 (fr) | 2007-06-28 | 2009-10-23 | Engelhard Lyon Soc Par Actions | Composition amincissante |
WO2009000935A1 (en) * | 2007-06-28 | 2008-12-31 | Basf Beauty Care Solutions France Sas | Slimming composition |
US8153611B2 (en) * | 2007-06-28 | 2012-04-10 | Basf Beauty Care Solutions France S.A.S. | Use of sulfated oligosaccharides as slimming cosmetic ingredients |
US20100266558A1 (en) * | 2007-12-18 | 2010-10-21 | Dov Zipori | Method and assay for glycosylation pattern detection related to cell state of stem cells |
KR101529061B1 (ko) * | 2008-05-30 | 2015-06-16 | 모멘타 파머슈티컬스 인코포레이티드 | 당류 구조물, 그리고 이러한 구조물의 제조 및 사용 방법 |
EP2149580A1 (en) | 2008-07-15 | 2010-02-03 | Istituto Scientifico di Chimica E Biochimica "G Ronzoni | Mimetics of sulfated oligosaccharides |
US8809009B2 (en) | 2009-01-02 | 2014-08-19 | Biomarin Pharmaceutical Inc. | Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker |
US8592140B2 (en) | 2009-01-02 | 2013-11-26 | Biomarin Pharmaceutical Inc. | Detection of oligosaccharides |
US9029530B2 (en) | 2009-01-02 | 2015-05-12 | Biomarin Pharmaceutical Inc. | Detection of oligosaccharides |
US8232073B2 (en) | 2009-01-02 | 2012-07-31 | Zacharon Pharmaceuticals, Inc. | Quantification of non-reducing end glycan residual compounds |
GB0915315D0 (en) | 2009-09-03 | 2009-10-07 | Univ Manchester | Use of non-digestible oligosaccharides |
JP5701498B2 (ja) * | 2009-12-01 | 2015-04-15 | 公益財団法人微生物化学研究会 | 炎症性細胞からのヘパラナーゼの放出抑制剤、抗炎症剤、及び薬用組成物 |
WO2011090948A1 (en) * | 2010-01-19 | 2011-07-28 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
US9226939B2 (en) * | 2010-12-01 | 2016-01-05 | The Australian National University | Histone inhibition |
WO2012112953A2 (en) * | 2011-02-18 | 2012-08-23 | President And Fellows Of Harvard College | Molecular switch for neuronal outgrowth |
WO2012115952A1 (en) | 2011-02-21 | 2012-08-30 | Momenta Pharmaceuticals, Inc. | Evaluating heparin preparations |
CN102199175A (zh) * | 2011-04-07 | 2011-09-28 | 福州大学 | 硫酸类肝素二糖的制备纯化方法及其纯化产品 |
EP3415153A1 (en) * | 2012-01-30 | 2018-12-19 | Baxalta GmbH | Non-anticoagulant sulfated or sulfonated polysaccharides |
RU2700877C2 (ru) * | 2013-05-16 | 2019-09-23 | Эдженси Фо Сайенс, Текнолоджи Энд Ресёрч | Гепарансульфаты |
JP2017515898A (ja) | 2014-05-08 | 2017-06-15 | イミューンエクサイト, インコーポレイテッド | 免疫調節β−1,6−D−グルカン |
SE538503C2 (en) * | 2014-11-11 | 2016-08-16 | Tx Medic Ab | New dextran sulfate |
CZ306662B6 (cs) * | 2015-06-26 | 2017-04-26 | Contipro A.S. | Deriváty sulfatovaných polysacharidů, způsob jejich přípravy, způsob jejich modifikace a použití |
CN105504097B (zh) * | 2015-12-30 | 2018-07-03 | 深圳市海普瑞药业集团股份有限公司 | 一种硫酸化肝素寡糖及其制备方法和应用 |
CA3046997A1 (en) | 2016-12-13 | 2018-06-21 | Beta Therapeutics Pty Ltd | Heparanase inhibitors and use thereof |
US11787783B2 (en) | 2016-12-13 | 2023-10-17 | Beta Therapeutics Pty Ltd | Heparanase inhibitors and use thereof |
WO2019118525A1 (en) * | 2017-12-12 | 2019-06-20 | Academia Sinica | Octasaccharides and uses thereof |
WO2019113646A1 (en) * | 2017-12-15 | 2019-06-20 | Griffith University | Sulfation method |
NL2024493B1 (en) * | 2019-12-16 | 2021-09-02 | Logick Energetics B V | Pharmaceutical composition for preventing or stopping metastases |
US20230023285A1 (en) | 2019-12-18 | 2023-01-26 | Logick Energetics B.V. | Pharmaceutical composition for use in preventing or stopping metastases |
CN110917208B (zh) * | 2019-12-27 | 2021-02-12 | 浙江医院 | 硫酸化甘露葡萄糖醛酸六糖在防治动脉粥样硬化中的应用 |
CN111904968A (zh) * | 2020-08-21 | 2020-11-10 | 青岛市中心医院 | 硫酸半乳四糖及其衍生物在制备抗上皮细胞黏附药物中的应用 |
CN114134188B (zh) * | 2021-07-23 | 2023-03-17 | 光明乳业股份有限公司 | 一种发酵小麦麸皮合成胞外多糖的方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62190127A (ja) * | 1985-12-24 | 1987-08-20 | マリオン・ラボラトリ−ズ・インコ−ポレ−テツド | 傷の治癒を促進するための合成多硫酸化オリゴ糖含有組成物 |
JPH0296588A (ja) * | 1988-09-29 | 1990-04-09 | Rikagaku Kenkyusho | 硫酸化オリゴ糖及びその関連物質 |
JPH03145496A (ja) * | 1989-10-30 | 1991-06-20 | Dainippon Ink & Chem Inc | オリゴ糖誘導体 |
JPH0578382A (ja) * | 1990-08-23 | 1993-03-30 | Dainippon Ink & Chem Inc | 硫酸化アルキルオリゴ糖またはその生理学的に許容される塩およびこれを有効成分とする抗ウイルス剤 |
JPH0597884A (ja) * | 1991-03-13 | 1993-04-20 | F Hoffmann La Roche Ag | 腸管内又は非経口投与用薬剤 |
JPH06506973A (ja) * | 1991-04-17 | 1994-08-04 | グライコメッド インコーポレイテッド | 平滑筋細胞増殖のインヒビターとしての硫酸化多糖類 |
JPH06256373A (ja) * | 1993-01-11 | 1994-09-13 | Dainippon Ink & Chem Inc | 硫酸化オリゴ糖配糖体アシル化物およびこれを有効成分とする抗ウイルス剤 |
WO1995009637A1 (en) * | 1993-10-07 | 1995-04-13 | Glycomed Incorporated | Highly sulfated maltooligosaccharides with heparin-like properties |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2597484B1 (fr) * | 1986-04-17 | 1988-12-23 | Sanofi Sa | Glycosaminoglycanes de type heparine ou heparane-sulfate dotes d'une activite sur la division et la differentiation cellulaires, leur preparation et leurs applications therapeutiques. |
US5541166A (en) * | 1987-01-23 | 1996-07-30 | The Australian National University | Sulphated polysaccharides having anti-metastatic and/or anti-inflammatory activity |
WO1989003684A1 (en) * | 1987-10-30 | 1989-05-05 | Chugai Seiyaku Kabushiki Kaisha | Anti-hiv agent |
US5506210A (en) * | 1988-08-19 | 1996-04-09 | The Australian National University | Phosphosugar-based anti-inflammatory and/or immunosuppressive drugs |
US5459257A (en) * | 1993-01-11 | 1995-10-17 | Dainippon Ink And Chemicals, Inc. | Sulfated oligoglycoside acylate and antiviral agent containing the same as active ingredient |
FR2710741B1 (fr) * | 1993-09-30 | 1995-10-27 | Commissariat Energie Atomique | Capteur électronique destiné à la caractérisation de grandeurs physiques et procédé de réalisation d'un tel capteur. |
US5739115A (en) * | 1993-10-07 | 1998-04-14 | Glycomed Incorporated | Sulfated maltooligosaccharides with heparin-like properties |
-
1995
- 1995-04-28 AU AUPN2618A patent/AUPN261895A0/en not_active Abandoned
-
1996
- 1996-04-24 TR TR97/01264T patent/TR199701264T1/xx unknown
- 1996-04-24 ES ES96910861T patent/ES2341924T3/es not_active Expired - Lifetime
- 1996-04-24 EP EP96910861A patent/EP0837683B1/en not_active Expired - Lifetime
- 1996-04-24 DE DE69638158T patent/DE69638158D1/de not_active Expired - Lifetime
- 1996-04-24 US US08/945,937 patent/US6143730A/en not_active Expired - Lifetime
- 1996-04-24 PT PT96910861T patent/PT837683E/pt unknown
- 1996-04-24 EA EA199700347A patent/EA001199B1/ru not_active IP Right Cessation
- 1996-04-24 AT AT96910861T patent/ATE463250T1/de not_active IP Right Cessation
- 1996-04-24 KR KR1019970707723A patent/KR100591960B1/ko not_active IP Right Cessation
- 1996-04-24 CZ CZ973410A patent/CZ341097A3/cs unknown
- 1996-04-24 CN CN96193563A patent/CN1090021C/zh not_active Expired - Lifetime
- 1996-04-24 JP JP53203896A patent/JP4514240B2/ja not_active Expired - Lifetime
- 1996-04-24 NZ NZ305815A patent/NZ305815A/xx not_active IP Right Cessation
- 1996-04-24 BR BRPI9608041-8B8A patent/BR9608041B8/pt not_active IP Right Cessation
- 1996-04-24 PL PL96323080A patent/PL184357B1/pl unknown
- 1996-04-24 HU HU9802394A patent/HUP9802394A2/hu unknown
- 1996-04-24 EE EE9700277A patent/EE9700277A/xx unknown
- 1996-04-24 CA CA002218872A patent/CA2218872C/en not_active Expired - Lifetime
- 1996-04-24 WO PCT/AU1996/000238 patent/WO1996033726A1/en not_active Application Discontinuation
- 1996-04-25 TW TW085104940A patent/TW446710B/zh not_active IP Right Cessation
- 1996-04-26 IL IL11804796A patent/IL118047A/xx not_active IP Right Cessation
- 1996-04-26 ZA ZA963339A patent/ZA963339B/xx unknown
-
1997
- 1997-10-21 IS IS4596A patent/IS4596A/is unknown
- 1997-10-24 NO NO974911A patent/NO974911L/no not_active Application Discontinuation
- 1997-10-27 FI FI974060A patent/FI974060A0/fi unknown
-
2009
- 2009-06-09 JP JP2009138310A patent/JP2009235085A/ja not_active Withdrawn
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62190127A (ja) * | 1985-12-24 | 1987-08-20 | マリオン・ラボラトリ−ズ・インコ−ポレ−テツド | 傷の治癒を促進するための合成多硫酸化オリゴ糖含有組成物 |
JPH0296588A (ja) * | 1988-09-29 | 1990-04-09 | Rikagaku Kenkyusho | 硫酸化オリゴ糖及びその関連物質 |
JPH03145496A (ja) * | 1989-10-30 | 1991-06-20 | Dainippon Ink & Chem Inc | オリゴ糖誘導体 |
JPH0578382A (ja) * | 1990-08-23 | 1993-03-30 | Dainippon Ink & Chem Inc | 硫酸化アルキルオリゴ糖またはその生理学的に許容される塩およびこれを有効成分とする抗ウイルス剤 |
JPH0597884A (ja) * | 1991-03-13 | 1993-04-20 | F Hoffmann La Roche Ag | 腸管内又は非経口投与用薬剤 |
JPH06506973A (ja) * | 1991-04-17 | 1994-08-04 | グライコメッド インコーポレイテッド | 平滑筋細胞増殖のインヒビターとしての硫酸化多糖類 |
JPH06256373A (ja) * | 1993-01-11 | 1994-09-13 | Dainippon Ink & Chem Inc | 硫酸化オリゴ糖配糖体アシル化物およびこれを有効成分とする抗ウイルス剤 |
WO1995009637A1 (en) * | 1993-10-07 | 1995-04-13 | Glycomed Incorporated | Highly sulfated maltooligosaccharides with heparin-like properties |
JPH09503510A (ja) * | 1993-10-07 | 1997-04-08 | グリコメド・インコーポレイテッド | ヘパリン様特性を有する高硫酸化マルトオリゴ糖 |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001513569A (ja) * | 1997-08-28 | 2001-09-04 | ユニバーシティ・オブ・ワシントン | アルツハイマー病および他のアミロイド症を治療するための特定の糖組成物 |
JP4659209B2 (ja) * | 1997-08-28 | 2011-03-30 | ユニバーシティ・オブ・ワシントン | アルツハイマー病および他のアミロイド症を治療するための特定の糖組成物 |
JP2002029974A (ja) * | 2000-07-10 | 2002-01-29 | Seikagaku Kogyo Co Ltd | 脱髄性疾患処置剤 |
JP4676048B2 (ja) * | 2000-07-10 | 2011-04-27 | 生化学工業株式会社 | 脱髄性疾患処置剤 |
JP2010506858A (ja) * | 2006-10-20 | 2010-03-04 | ジ オーストラリアン ナショナル ユニバーシティ | 細胞外マトリクスの分解の阻害 |
JP2015164947A (ja) * | 2007-10-16 | 2015-09-17 | プロジェン ファーマシューティカルズ リミテッド | 新規硫酸化オリゴ糖誘導体 |
WO2011122321A1 (ja) * | 2010-03-29 | 2011-10-06 | 国立大学法人名古屋大学 | ヘパリン結合性蛋白に対する生理活性阻害剤 |
JPWO2011122321A1 (ja) * | 2010-03-29 | 2013-07-08 | 国立大学法人名古屋大学 | ヘパリン結合性蛋白に対する生理活性阻害剤 |
JP2014516058A (ja) * | 2011-06-09 | 2014-07-07 | 基亜生物科技股▲ふん▼有限公司 | 肝癌の再発、悪化または転移の抑制に用いる医薬組成物 |
JP2016199579A (ja) * | 2016-07-08 | 2016-12-01 | 基亜生物科技股▲ふん▼有限公司Medigen Biotechnology Corp. | 肝癌の再発、悪化または転移の抑制に用いる医薬組成物 |
JP2018109039A (ja) * | 2018-02-22 | 2018-07-12 | 基亜生物科技股▲ふん▼有限公司Medigen Biotechnology Corp. | 肝癌の再発、悪化または転移の抑制に用いる医薬組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11504018A (ja) | 硫酸化オリゴ糖の製造および使用 | |
Volpi | Therapeutic applications of glycosaminoglycans | |
FI88046C (fi) | Foerfarande foer framstaellning av hepariner med laog molekylvikt | |
CA1171375A (en) | Oligosaccharides having selective anticoagulation activity | |
KR100855331B1 (ko) | 혈관형성 억제 활성을 가지며 응고억제 효과는 없는,헤파라나제 억제제로서 부분적으로 탈황산화된글리코스아미노글리칸의 유도체 | |
JP2001527583A (ja) | ヘパリンのo−脱硫酸化の制御方法およびそれによって得られる組成物 | |
WO1994014849A1 (en) | Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation | |
JPH06506685A (ja) | 新規な非抗凝固剤ヘパリン誘導体 | |
EP2025687A1 (en) | Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby | |
JP4434741B2 (ja) | 女性の有効な分娩を確立するための硫酸化グリコサミノグリカンの使用 | |
US20050245736A1 (en) | Low molecular weight oversulfated polysaccharide | |
JP4412756B2 (ja) | 新規多糖誘導体、その製造法及びそれを有効成分とする医薬組成物 | |
JP4019128B2 (ja) | 抗ヘルペスウイルス剤 | |
WO1999043714A1 (fr) | Nouveaux derives de polysaccharide, leur procede de production, et compositions medicinales contenant ces nouveaux derives comme principe actif | |
JP4462826B2 (ja) | 骨疾患治療剤 | |
AU702500B2 (en) | Preparation and use of sulfated oligosaccharides | |
JP4282267B2 (ja) | 硫酸化フコビオシルコンドロイチン硫酸誘導体 | |
AU706002B2 (en) | New anticoagulants | |
MXPA97008289A (en) | Preparation and use of oligosacaridos sulfata | |
JP4462856B2 (ja) | 硫酸化ポリフコース及びその製造方法 | |
JPH02124902A (ja) | 血液凝固抑制剤 | |
ZA200410358B (en) | Low molecular weight oversulfated polysaccharide. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070116 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070413 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070604 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070607 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070702 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090511 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20090609 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20090511 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090806 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100315 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100420 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100511 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130521 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |